Results 161 to 170 of about 48,430 (295)

Boron‐10 carriers and their applications in boron neutron capture therapy

Precision Radiation Oncology, EarlyView.
Summary of different types of boron drugs. Abstract Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10B(n,α)7Li nuclear reaction with minimal side effects on normal tissues.
Dachao Tang, Mengqi Shi, Zhichen Mao, Weiya Chen, Xiaoling Li, Xiao Yan Zhao, Zhigang Liu, Xiao Xu   +7 more
wiley   +1 more source

Evaluating 7‑Aminopyrazolo[4,3‑<i>d</i>]pyrimidines as Human A₁ and A₃ Adenosine Receptor Antagonists. [PDF]

ACS Omega
Georgiou K, Lamprakopoulou M, Buthmann H, Böing S, Pousias A, Dexter A, Chew EXY, Huang X, Michalettou EI, Pearce A, Dotsikas Y, Pouli N, Marakos P, Kolocouris A, Ladds G, Lougiakis N.   +15 more
europepmc   +1 more source

Emerging Agents for Boron Neutron Capture Therapy: Biomolecular Carriers Paving the Way for Precision Radiotherapy

Precision Radiation Oncology, EarlyView.
Boron neutron capture therapy (BNCT) requires key non‐negotiable technical criteria: megadose administration, precise tumor‐specific targeting, favorable biocompatibility, and sustained tumor retention. Overcoming these interconnected challenges fundamentally depends on biomolecular carriers, which are critical for translating the therapeutic potential
Chang Chen, Maosong Yang, Jiheng Wang, Ling Zhang, Shaobo Huang, Xiao Xu, Yang Liu   +6 more
wiley   +1 more source

The continuing significance of chiral agrochemicals

Pest Management Science, Volume 81, Issue 4, Page 1697-1716, April 2025.
In the time frame 2018–2023, around 43% of the 35 chiral agrochemicals introduced to the market (herbicides, fungicides, insecticides, acaricides, and nematicides) contain one or more stereogenic centers in the molecule, and almost 69% of them have been marketed as racemic mixtures of enantiomers or stereoisomers.
Peter Jeschke
wiley   +1 more source

The antitumor promise of furo[2,3-<i>d</i>]pyrimidine: a 2016-2025 review. [PDF]

RSC Adv
Mansour MA, Elshafei HA, Sayed AS, Ashour AA, Hussein NE, Abdel Karim MM, Kamel FM, Elsayed NT, Ahmed MR, Seleem MT, Gomaa RM.   +10 more
europepmc   +1 more source

Synthesis and Flash Vacuum Pyrolysis of Isoxazolo[5,4-D]Pyrimidines and Isothiazolo[5,4-D]Pyrimidines

, 1994
The multi-step synthesis of isothiazolo[5,4-d]pyrimidines (1c,d) and isoxazolo[5,4-d]pyrimidine (1b) is described. Flash vacuum pyrolysis of lb leads to phenyliminopropadienone, Ph-N=C=C=C=O, which was identified by Ar matrix infrared ...
Wentrup, C, Flammang, R, Kappe, CO
core  

Natural Products as Modulators of ABC Transporters in Breast Cancer

Phytotherapy Research, EarlyView.
ABSTRACT Breast cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in early detection and treatment. Multidrug resistance (MDR), particularly in aggressive subtypes like triple‐negative breast cancer (TNBC), continues to hinder effective therapy.
Yoganishalini Sagadevan, Reyhaneh Farghadani, Ammu K. Radhakrishnan   +2 more
wiley   +1 more source

Recent green approaches for the synthesis of thienopyrimidine scaffolds: an overview (2007-2025). [PDF]

RSC Adv
Rabeh RM, Kassab AE, Hassan RA, Shahin IG.   +3 more
europepmc   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Synthesis of new pyrazolo[3,4-d]pyrimidines as potential mutant EGFR/HER2 and Bcl2 inhibitors: anticancer evaluation, DFT, molecular docking and ADME studies. [PDF]

BMC Chem
Metwally NH, Saad ZA, Mohamed MS.
europepmc   +1 more source